After breast-conserving surgery and adjuvant endocrine therapy, whole breast irradiation can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.
Tony Berberabe, MPH
Advertisement
Articles by Tony Berberabe, MPH
The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.
The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
2
FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer
3
Atirmociclib/Fulvestrant Improves PFS in HR+/HER2– Breast Cancer
4
Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers
5